XY Capital Ltd Purchases New Stake in Dr. Reddy's Laboratories Limited (NYSE:RDY)

XY Capital Ltd bought a new position in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 67,209 shares of the company's stock, valued at approximately $1,061,000. Dr. Reddy's Laboratories accounts for 0.5% of XY Capital Ltd's holdings, making the stock its 19th biggest holding.

Several other hedge funds have also made changes to their positions in RDY. Savant Capital LLC acquired a new position in Dr. Reddy's Laboratories during the 4th quarter valued at about $220,000. Migdal Insurance & Financial Holdings Ltd. increased its position in Dr. Reddy's Laboratories by 217.5% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 100,000 shares of the company's stock valued at $1,571,000 after buying an additional 68,500 shares in the last quarter. Adero Partners LLC increased its position in Dr. Reddy's Laboratories by 179.4% during the 4th quarter. Adero Partners LLC now owns 11,415 shares of the company's stock valued at $180,000 after buying an additional 7,329 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Dr. Reddy's Laboratories by 382.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 18,666 shares of the company's stock valued at $293,000 after buying an additional 14,800 shares in the last quarter. Finally, Yousif Capital Management LLC increased its position in Dr. Reddy's Laboratories by 400.0% during the 4th quarter. Yousif Capital Management LLC now owns 12,785 shares of the company's stock valued at $202,000 after buying an additional 10,228 shares in the last quarter. 3.85% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

RDY has been the topic of several recent analyst reports. Barclays reduced their target price on Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 6th. StockNews.com lowered Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a report on Friday, December 6th. Finally, Nomura lowered Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a report on Thursday, December 19th.

Dr. Reddy's Laboratories Stock Performance

Shares of RDY traded up $0.22 during mid-day trading on Thursday, reaching $14.02. The company had a trading volume of 2,497,317 shares, compared to its average volume of 2,006,514. Dr. Reddy's Laboratories Limited has a 52-week low of $13.36 and a 52-week high of $16.89. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $11.70 billion, a P/E ratio of 22.32 and a beta of 0.50. The stock has a 50 day moving average of $14.75 and a two-hundred day moving average of $15.32.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. On average, analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current year.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.